MindWalk Holdings (HYFT) Share-based Compensation (IS) (2020 - 2024)
MindWalk Holdings (HYFT) reported Share-based Compensation (IS) of $120501.5 for Q3 2024, down 80.46% year-over-year from $616594.7 in Q3 2023, and down 8.48% quarter-over-quarter from $131670.4 in Q1 2024.
MindWalk Holdings (HYFT) Share-based Compensation (IS) (2020 - 2024) Analysis & Trends
MindWalk Holdings (HYFT) has 5 years of Share-based Compensation (IS) data on file, last reported at $120501.5 in Q3 2024.
- Share-based Compensation (IS) for Q3 2024 came in at $120501.5, down 80.46% year-over-year; the trailing twelve-month figure through Jul 2024 was $1.1 million (down 31.95% YoY), and the FY2022 annual result was $2.4 million, up 12.14% from the prior year.
- Share-based Compensation (IS) slipped to $120501.5 in Q3 2024 per HYFT's latest filing, from $131670.4 in the prior quarter.
- Over five years, Share-based Compensation (IS) peaked at $2.4 million in Q2 2022 and troughed at $548.06 in Q4 2021.
- A 5-year average of $477405.8 and a median of $181062.4 in 2023 frame the typical range for Share-based Compensation (IS).
- On a YoY basis, Share-based Compensation (IS) climbed as much as 152782.98% in 2022 and fell as far as 99.9% in 2022.
- A 5-year view of Share-based Compensation (IS) shows it stood at $360769.1 in 2020, then slumped by 99.85% to $548.06 in 2021, then jumped by 152782.98% to $837885.3 in 2022, then tumbled by 73.86% to $219035.7 in 2023, then slumped by 44.99% to $120501.5 in 2024.
- Business Quant data shows HYFT's Share-based Compensation (IS) at $120501.5 in Q3 2024, $131670.4 in Q1 2024, and $219035.7 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 1.45 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 892,057.00 |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 14.90 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | MindWalk Holdings | 166.20 Mn | 156.06 Mn | 1.78 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2024 | 120,501.48 |
| Jul 31, 2024 | 120,501.48 |
| Jan 31, 2024 | 131,670.42 |
| Jan 31, 2024 | 131,670.42 |
| Oct 31, 2023 | 219,035.68 |
| Oct 31, 2023 | 219,035.68 |
| Jul 31, 2023 | 616,594.73 |
| Jul 31, 2023 | 616,594.73 |
| Jan 31, 2023 | 143,089.12 |
| Jan 31, 2023 | 143,089.12 |
| Oct 31, 2022 | 837,885.27 |
| Oct 31, 2022 | 837,885.27 |
| Jul 31, 2022 | 867.72 |
| Jul 31, 2022 | 867.72 |
| Apr 30, 2022 | 2.45 Mn |
| Apr 30, 2022 | 2.45 Mn |
| Jan 31, 2022 | 673.15 |
| Jan 31, 2022 | 673.15 |
| Oct 31, 2021 | 548.06 |
| Oct 31, 2021 | 548.06 |